Roth Capital Affirms Neuralstem (CUR) at 'Buy' Amid NSI-189 Enrollment Milestone

Roth Capital affirms Neuralstem (Nasdaq: CUR) with a Buy rating and $1.20 price target after the company announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder (MDD).

Analyst Joseph Pantginis commented today, We believe that the timely achievement of 50% study enrollment in the Phase IIb trial highlights the efforts that CUR and management are making to keep the company focused on its lead compound, NSI-189. Importantly, the present enrollment rate keeps the target time for data release in 2H17. According to our projections, the additional funding from the September raise gives CUR ~1.5 years of runway.

For an analyst ratings summary and ratings history on Neuralstem click here. For more ratings news on Neuralstem click here.

You May Also Be Interested In

• CFRA Upgrades Alstom SA (ALO:FP) (ALSMY) to Hold
• Argus on ASML Inc. (ASML): 'Remaining cautious on 2024'
• ImmunityBio (IBRX) Announces FDA Approval of ANKTIVA